ISNO Position Statement on Treatment Guidance in Neuro-oncology During Pandemics
ISNO Position Statement on Treatment Guidance in Neuro-oncology During Pandemics
复制标题
DOI：
10.4103/0028-3886.293460
复制
发表时间：
2020-07-01
期刊：
影响因子：
2.7
通讯作者：
Jalali, Rakesh
中科院分区：
文献类型：
--
作者：
Gupta, Tejpal;Singh, Varindera P.;Jalali, Rakesh
包括印度在内的整个世界目前都在抗击冠状病毒病19（COVID-19）大流行，这可能会在能力和资源方面扰乱全球医疗保健系统。这次爆发需要紧急审查现有的管理指南，常见的脑和中枢神经系统（CNS）肿瘤。这种审查应包括重新评估获益风险比，以符合地方、国家和国际优先事项，而不影响在安全性、同情心、效率和有效性方面提供护理。为此，印度神经肿瘤学会（ISNO）成立了一个在线专家小组，由所有主要治疗方式（神经外科、放射肿瘤学和儿科/内科肿瘤学）的充分代表组成，以制定“COVID-19背景”立场声明，指导在持续危机期间对神经肿瘤患者的护理。ISNO立场声明建议分级优先（基于临床表现、肿瘤类型、预期预后和即时治疗的相关性），以有效利用资源，并通过一组一般考虑因素、基于治疗方式的考虑因素和疾病特异性考虑因素提供框架，以指导参与向CNS肿瘤患者提供护理和服务的医疗保健专业人员。本文所表达的观点代表了印度神经肿瘤学界主要意见领袖的当前共识，在任何情况下都不应被视为对个体医生和/或医院具有医学或法律约束力，个体医生和/或医院可根据当地设置和健康环境制定其指南，并根据COVID-19大流行期间出现的证据定期更新。
The entire world including India is currently fighting the coronavirus disease 19 (COVID-19) pandemic that threatens to disrupt healthcare systems globally in terms of capacity and resources. This outbreak necessitates an urgent review of existing management guidelines for commonly encountered tumors of the brain and central nervous system (CNS). Such a review should include a reassessment of benefit-risk ratio to align with local, national, and international priorities without compromising on delivery of care in terms of safety, compassion, efficiency, and effectiveness. Towards this end, the Indian Society of Neuro-Oncology (ISNO) constituted an online expert panel with adequate representation from all major treatment modalities (neuro-surgery, radiation oncology, and pediatric/medical oncology) to formulate a "COVID-19 context" position statement to guide the care of neuro-oncology patients during the ongoing crisis. The ISNO position statement suggests graded prioritization (based on clinical presentation, type of tumor, expected prognosis, and relevance of immediate therapy) for efficient utilization of resources and provides a framework through a set of general considerations, treatment modality-based considerations, and disease-specific considerations for the guidance of healthcare professionals involved in the delivery of care and services to patients with CNS tumors. The views expressed herein represent the current consensus of key opinion leaders from within the Indian neuro-oncology community and should not be in any case considered binding medically or legally to individual physicians and/or hospitals who may formulate their guidelines based on local setup and health-environment and update them periodically based on emerging evidence through the COVID-19 pandemic.